In vitro effect of carboplatin, cytarabine, paclitaxel, vincristine, and low-power laser irradiation on murine mesenchymal stem cells

Károly Horvát-Karajz, Zsuzsanna Balogh, Viktória Kovács, András Hámori, Lídia Sréter, F. Uher

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background and Objectives: Mesenchymal stem cells (MSCs) are promising for use in regenerative medicine. Cytostatics can decrease, but low-power laser irradiation (LPLI) can increase the growth of MSCs. The interaction of LPLI, MSCs and cytostatics is not known. This study investigated the effect of four cytostatics (carboplatin, cytarabine, paclitaxel, vincristine), LPLI, and combination of a cytostatic drug and LPLI on murine MSCs (mMSCs). Study Design/Materials and Methods: MMSCs were exposed to LPLI (660nm diode laser; 60mW output power; range of power density: 76-156mW/cm2; range of energy density: 1.9-11.7 J/cm2) and/or a cytostatic drug (carboplatin: 2, 10, 50; cytarabine: 0.4, 10, 50; paclitaxel: 0.4, 2, 10; vincristine: 0.02, 0.1, 0.5 μg/ml, respectively). Cell proliferation was measured after 24, 48, or 72 hours incubation. Results: LPLI at 1.9 J/cm 2 dose increased the proliferation rate with 41% after 48 hours. However, 11.7 J/cm2 LPLI caused 42% inhibition and cytostasis was still detectable after 72 hours. LPLI caused equivalent stimulation in single or in divided doses (3.8 vs. double 1.9 J/cm2 in a 24-hour period). The cytotoxicity of 50 μg/ml carboplatin was eliminated, the inhibitory power of 0.1 μg/ml vincristine was attenuated by 1.9 J/cm2 LPLI even 3 days post-treatment (attenuation > 10%). The 11.7 J/cm2 LPLI enhanced the cytotoxicity of 50 μg/ml cytarabine (from 48% to 73%) and 10 μg/ml paclitaxel (from 37% to 78%). Combination of the ineffective 0.4 μg/ml cytarabine or paclitaxel with the inhibitory 11.7 J/cm2 LPLI exhibited stronger inhibition than the 11.7 J/cm2 LPLI alone (69% and 69% vs. 42%). Conclusions: Low energy density of LPLI increases and high energy density of LPLI decreases the proliferation of mMSCs. Furthermore, LPLI can prevent or attenuate some drug's cytotoxicity and amplify others'. The result depends on the applied energy density, on the type and concentration of the cytostatics.

Original languageEnglish
Pages (from-to)463-469
Number of pages7
JournalLasers in Surgery and Medicine
Volume41
Issue number6
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Carboplatin
Cytarabine
Vincristine
Paclitaxel
Mesenchymal Stromal Cells
Cytostatic Agents
In Vitro Techniques
Low-Level Light Therapy
Semiconductor Lasers
Regenerative Medicine

Keywords

  • Cell proliferation
  • Cytostatics
  • Inhibition
  • Laser biostimulation
  • Laser-induced
  • Low-level laser therapy
  • Protection

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

In vitro effect of carboplatin, cytarabine, paclitaxel, vincristine, and low-power laser irradiation on murine mesenchymal stem cells. / Horvát-Karajz, Károly; Balogh, Zsuzsanna; Kovács, Viktória; Hámori, András; Sréter, Lídia; Uher, F.

In: Lasers in Surgery and Medicine, Vol. 41, No. 6, 08.2009, p. 463-469.

Research output: Contribution to journalArticle

Horvát-Karajz, Károly ; Balogh, Zsuzsanna ; Kovács, Viktória ; Hámori, András ; Sréter, Lídia ; Uher, F. / In vitro effect of carboplatin, cytarabine, paclitaxel, vincristine, and low-power laser irradiation on murine mesenchymal stem cells. In: Lasers in Surgery and Medicine. 2009 ; Vol. 41, No. 6. pp. 463-469.
@article{6b0a87f16af74494b3b386f56c8fe3dc,
title = "In vitro effect of carboplatin, cytarabine, paclitaxel, vincristine, and low-power laser irradiation on murine mesenchymal stem cells",
abstract = "Background and Objectives: Mesenchymal stem cells (MSCs) are promising for use in regenerative medicine. Cytostatics can decrease, but low-power laser irradiation (LPLI) can increase the growth of MSCs. The interaction of LPLI, MSCs and cytostatics is not known. This study investigated the effect of four cytostatics (carboplatin, cytarabine, paclitaxel, vincristine), LPLI, and combination of a cytostatic drug and LPLI on murine MSCs (mMSCs). Study Design/Materials and Methods: MMSCs were exposed to LPLI (660nm diode laser; 60mW output power; range of power density: 76-156mW/cm2; range of energy density: 1.9-11.7 J/cm2) and/or a cytostatic drug (carboplatin: 2, 10, 50; cytarabine: 0.4, 10, 50; paclitaxel: 0.4, 2, 10; vincristine: 0.02, 0.1, 0.5 μg/ml, respectively). Cell proliferation was measured after 24, 48, or 72 hours incubation. Results: LPLI at 1.9 J/cm 2 dose increased the proliferation rate with 41{\%} after 48 hours. However, 11.7 J/cm2 LPLI caused 42{\%} inhibition and cytostasis was still detectable after 72 hours. LPLI caused equivalent stimulation in single or in divided doses (3.8 vs. double 1.9 J/cm2 in a 24-hour period). The cytotoxicity of 50 μg/ml carboplatin was eliminated, the inhibitory power of 0.1 μg/ml vincristine was attenuated by 1.9 J/cm2 LPLI even 3 days post-treatment (attenuation > 10{\%}). The 11.7 J/cm2 LPLI enhanced the cytotoxicity of 50 μg/ml cytarabine (from 48{\%} to 73{\%}) and 10 μg/ml paclitaxel (from 37{\%} to 78{\%}). Combination of the ineffective 0.4 μg/ml cytarabine or paclitaxel with the inhibitory 11.7 J/cm2 LPLI exhibited stronger inhibition than the 11.7 J/cm2 LPLI alone (69{\%} and 69{\%} vs. 42{\%}). Conclusions: Low energy density of LPLI increases and high energy density of LPLI decreases the proliferation of mMSCs. Furthermore, LPLI can prevent or attenuate some drug's cytotoxicity and amplify others'. The result depends on the applied energy density, on the type and concentration of the cytostatics.",
keywords = "Cell proliferation, Cytostatics, Inhibition, Laser biostimulation, Laser-induced, Low-level laser therapy, Protection",
author = "K{\'a}roly Horv{\'a}t-Karajz and Zsuzsanna Balogh and Vikt{\'o}ria Kov{\'a}cs and Andr{\'a}s H{\'a}mori and L{\'i}dia Sr{\'e}ter and F. Uher",
year = "2009",
month = "8",
doi = "10.1002/lsm.20791",
language = "English",
volume = "41",
pages = "463--469",
journal = "Lasers in Surgery and Medicine",
issn = "0196-8092",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - In vitro effect of carboplatin, cytarabine, paclitaxel, vincristine, and low-power laser irradiation on murine mesenchymal stem cells

AU - Horvát-Karajz, Károly

AU - Balogh, Zsuzsanna

AU - Kovács, Viktória

AU - Hámori, András

AU - Sréter, Lídia

AU - Uher, F.

PY - 2009/8

Y1 - 2009/8

N2 - Background and Objectives: Mesenchymal stem cells (MSCs) are promising for use in regenerative medicine. Cytostatics can decrease, but low-power laser irradiation (LPLI) can increase the growth of MSCs. The interaction of LPLI, MSCs and cytostatics is not known. This study investigated the effect of four cytostatics (carboplatin, cytarabine, paclitaxel, vincristine), LPLI, and combination of a cytostatic drug and LPLI on murine MSCs (mMSCs). Study Design/Materials and Methods: MMSCs were exposed to LPLI (660nm diode laser; 60mW output power; range of power density: 76-156mW/cm2; range of energy density: 1.9-11.7 J/cm2) and/or a cytostatic drug (carboplatin: 2, 10, 50; cytarabine: 0.4, 10, 50; paclitaxel: 0.4, 2, 10; vincristine: 0.02, 0.1, 0.5 μg/ml, respectively). Cell proliferation was measured after 24, 48, or 72 hours incubation. Results: LPLI at 1.9 J/cm 2 dose increased the proliferation rate with 41% after 48 hours. However, 11.7 J/cm2 LPLI caused 42% inhibition and cytostasis was still detectable after 72 hours. LPLI caused equivalent stimulation in single or in divided doses (3.8 vs. double 1.9 J/cm2 in a 24-hour period). The cytotoxicity of 50 μg/ml carboplatin was eliminated, the inhibitory power of 0.1 μg/ml vincristine was attenuated by 1.9 J/cm2 LPLI even 3 days post-treatment (attenuation > 10%). The 11.7 J/cm2 LPLI enhanced the cytotoxicity of 50 μg/ml cytarabine (from 48% to 73%) and 10 μg/ml paclitaxel (from 37% to 78%). Combination of the ineffective 0.4 μg/ml cytarabine or paclitaxel with the inhibitory 11.7 J/cm2 LPLI exhibited stronger inhibition than the 11.7 J/cm2 LPLI alone (69% and 69% vs. 42%). Conclusions: Low energy density of LPLI increases and high energy density of LPLI decreases the proliferation of mMSCs. Furthermore, LPLI can prevent or attenuate some drug's cytotoxicity and amplify others'. The result depends on the applied energy density, on the type and concentration of the cytostatics.

AB - Background and Objectives: Mesenchymal stem cells (MSCs) are promising for use in regenerative medicine. Cytostatics can decrease, but low-power laser irradiation (LPLI) can increase the growth of MSCs. The interaction of LPLI, MSCs and cytostatics is not known. This study investigated the effect of four cytostatics (carboplatin, cytarabine, paclitaxel, vincristine), LPLI, and combination of a cytostatic drug and LPLI on murine MSCs (mMSCs). Study Design/Materials and Methods: MMSCs were exposed to LPLI (660nm diode laser; 60mW output power; range of power density: 76-156mW/cm2; range of energy density: 1.9-11.7 J/cm2) and/or a cytostatic drug (carboplatin: 2, 10, 50; cytarabine: 0.4, 10, 50; paclitaxel: 0.4, 2, 10; vincristine: 0.02, 0.1, 0.5 μg/ml, respectively). Cell proliferation was measured after 24, 48, or 72 hours incubation. Results: LPLI at 1.9 J/cm 2 dose increased the proliferation rate with 41% after 48 hours. However, 11.7 J/cm2 LPLI caused 42% inhibition and cytostasis was still detectable after 72 hours. LPLI caused equivalent stimulation in single or in divided doses (3.8 vs. double 1.9 J/cm2 in a 24-hour period). The cytotoxicity of 50 μg/ml carboplatin was eliminated, the inhibitory power of 0.1 μg/ml vincristine was attenuated by 1.9 J/cm2 LPLI even 3 days post-treatment (attenuation > 10%). The 11.7 J/cm2 LPLI enhanced the cytotoxicity of 50 μg/ml cytarabine (from 48% to 73%) and 10 μg/ml paclitaxel (from 37% to 78%). Combination of the ineffective 0.4 μg/ml cytarabine or paclitaxel with the inhibitory 11.7 J/cm2 LPLI exhibited stronger inhibition than the 11.7 J/cm2 LPLI alone (69% and 69% vs. 42%). Conclusions: Low energy density of LPLI increases and high energy density of LPLI decreases the proliferation of mMSCs. Furthermore, LPLI can prevent or attenuate some drug's cytotoxicity and amplify others'. The result depends on the applied energy density, on the type and concentration of the cytostatics.

KW - Cell proliferation

KW - Cytostatics

KW - Inhibition

KW - Laser biostimulation

KW - Laser-induced

KW - Low-level laser therapy

KW - Protection

UR - http://www.scopus.com/inward/record.url?scp=67650513658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650513658&partnerID=8YFLogxK

U2 - 10.1002/lsm.20791

DO - 10.1002/lsm.20791

M3 - Article

C2 - 19588531

AN - SCOPUS:67650513658

VL - 41

SP - 463

EP - 469

JO - Lasers in Surgery and Medicine

JF - Lasers in Surgery and Medicine

SN - 0196-8092

IS - 6

ER -